Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells.

Biochemical and biophysical research communications - 25 Jun 2026

Mehrotra Megha, Shenoy Priti S, Sakpal Asmita, Chakraborty Sourav, Ray Pritha

Abstract excerpt

BACKGROUND: Doxorubicin alone or in combination is widely used as first- or second-line chemotherapy in multiple solid tumors. Yet poor overall/progression-free survival and high mortality reflect the inherent Dox-resistance. Such resistance significantly limits the response to anthracycline-containing regimens. Frequent occurrence of TP53 mutations across cancers suggests that mutant-p53 may drive selective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A1

Share to DNA Topoisomerases, Type II

Share to Doxorubicin

Share to Drug Resistance, Neoplasm

Share to Poly-ADP-Ribose Binding Proteins

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42019355
DOI: 10.1016/j.bbrc.2026.153759

Genes

CYP1A1
TOP2A
BAX
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells.PMID 42019355Read ↗

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.Semantic proximity Read ↗

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.Semantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing ActSemantic proximity Read ↗

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic StrategiesSemantic proximity Read ↗

p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activitiesSemantic proximity Read ↗

The role of p53 in cancer drug resistance and targeted chemotherapy.Semantic proximity Read ↗

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.Semantic proximity Read ↗

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.Semantic proximity Read ↗

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistanceSemantic proximity Read ↗

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.